Envafolimab plus chemo for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced soft tissue sarcoma (a type of cancer in muscles, fat, or connective tissue) with at least one tumor that can be measured on scans.
- You must not have received any previous treatment for this cancer.
- You must be 18 years or older and expected to live at least 3 more months.
- Your blood counts and organ function (liver, kidneys, heart) must be within certain limits.
- You cannot be pregnant or breastfeeding, and if you are of childbearing age, you must agree to use contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests whether giving chemotherapy both before and after surgery helps people with high-risk soft tissue sarcoma live longer and prevents the cancer from coming back. It aims to see if this treatment plan is more effective than surgery alone.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
This trial tests a step-by-step (sequential) chemotherapy plan given before surgery for adults with specific types of soft tissue sarcoma. The goal is to shrink or control the tumor before the operation and see how well this approach works and is tolerated.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.